Protection of Intellectual Property in Canada George Jackowski, Ph.D., KCTJ October 19 th, 2015 Chairman of NAVA Corp.

Slides:



Advertisements
Similar presentations
WHY?WHAT?HOW?WHERE? Copyright © KATZAROV S.A.19/02/2007 Patents in the Electronic (and IT) Industries Olivier Sacroug European Patent Attorney Katzarov.
Advertisements

New Patent Issue: BioPharma Royalty Trust by Eugene Li Summary of pages From Ideas to Assets - Part 22.
CENTRAL OCTOBER 2012 EXPERTS MANAGEMENT KNOWLEDGE EUROPEAN IN.
GeneriKairos® making faster Generics. Molecule patent expiry date Later expiring patents - Need significant R&D, might delay generic drug development.
Hale & Tempest The Global Pharmaceutical Industry (MNC & Generic) in Transition Dr. Brian W Tempest The Global Generic Summit – Barcelona,
Peter D. Aufrichtig, Esq..  Intellectual Property clients look and sound like all other clients.
Have FDA Expedited Programs Shortened Drug Development Timelines? An analysis of newly approved therapies and how FDA expedited programs impacted drug.
An Overview of the Canadian Pharmaceutical Industry
What is a Generic Medication?. The World Health Organization Definition of a Generic Medication A generic drug is a pharmaceutical product, usually intended.
The Global Generic Medications Market
Intellectual Property Patent Primer Michael Pratt Executive Director, Business Development November 1, 2011.
CONFIDENTIAL PATENTS What You Need To Know Robert Benson Office of Technology Development Harvard University Brandeis University – October 20, 2005.
 Final Year Engineering Students May 2004 Soozy J Smith So you think you have an Idea?
Bullet Proof IP Perkins Coie LLP.  Full Service Firm slanted towards high tech companies  700 lawyers; 14 offices  Named one of the "Best 100 Companies"
DAVID HARDING CPhI 2008 SHANGHAI JUNE 24–26, 2008 Product Selection for API Manufacturers and Generic Pharmaceutical Companies: A Tool for Success.
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
 Daphne Sheridan Bass services a roster of clients in private practice in the cosmetics, personal care, pharmaceutical and fashion industries, including.
Sabena Ahmad Iveta Smincakova Dawn Bradbury. Political:  Lighter Regulatory Controls (1960s)  Tighter Regulatory Controls on Clinical trials (1970s)
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
Policy Issues Concerning Parallel Trade of Pharmaceutical Drugs in the United States James Love CPTech FDA Prescription Drug Importation Meeting 14 April.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
USPTO PCT Task Force Public Hearing January 13, 2010 Lawrence T. Welch Assistant General Patent Counsel Eli Lilly & Co.
The New USPTO Rules and their Impact on Biomedical Patent Prosecution Mojdeh Bahar, J.D.,M.A. Technology Licensing Specialist Office of Technology Transfer.
Hale & Tempest India Biotech Briefing Dr. Brian W Tempest IBIZ Conference, NHS Expo Excel London UK 9 March 2011.
Patent Cooperation Treaty and Application Conference September 24, 2012 Neal L. Slifkin 99 Garnsey Road Pittsford, NY (585)
Subsequent Entry Biologics (SEBs) – Canada Presentation to AIPLA Biotechnology Committee January 25, 2012 Daphne C. Lainson
A Basic Primer on Intellectual Property Kathryn Atchison, DDS, MPH Vice Provost, Intellectual Property and Industry Relations Associate Vice Chancellor.
INTELLECTUAL PROPERTY PROTECTION OF BIOTECH IN THE U.S. Marc S. Friedman Chair, Intellectual Property Practice Sills Cummis Epstein & Gross P.C. 30 Rockefeller.
Protecting Intellectual Property Around The World 6 th Annual The Security Summit Mitchell P. Brook Partner, Luce Forward
Japan Medical Device Market Overview Ian Clements Office of Japan U.S. Department of Commerce April 10, 2008.
INTRODUCTION TO RA.
The Patent Prosecution Highway: Strategic Considerations in Accelerating U.S. and Foreign Patent Prosecution ACC Quick Hits June 13, 2012 Dr. John K. McDonald.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
1 Investing in Innovation Should the EU do more to match US investment in innovative medicines? Brian Ager EFPIA Gastein, 6 October 2004.
The World Leader in High Performance Signal Processing Solutions Global Intellectual Property Protection December 2014 Jason Fiorillo Chief I.P. Counsel.
Anthony C. Tridico, Ph.D. AIPLA BIOTECHNOLOGY COMMITTEE Pinning Down a Moving Target: Patenting Biotech in Uncertain Times.
Veiovis LifeSciences Pvt Ltd
Fundamental Requirements for Patent Protection in the United States Chapter 3.
Entrepreneurship and Extracting Value from IP Dr. Corrinne Lobe Innovate LLP Entrepreneurship, Innovation and Commercialization of.
MFJ International, LLC A Global Consulting Firm “FTAs and Pharmaceuticals: a hijacked process?” M. Fabiana Jorge CPTECH November 16, 2006.
03/10/2008 Terese Rakow, PhD. Postdoctoral Career Development Course March 10, 2008.
© IFPMA 2009WIPO Open-ended Forum on Proposed Development Agenda Projects - 13/10/2009 IFPMA views on the strategic use of information for sustainable.
International Patent Filing: The University Perspective Technology Transfer Tactics August 5, 2010.
1 IP Regime and its Effect on Knowledge-Economy : South Korean IP Perspective October 2013.
An Alternative to Pharmaceutical Patents Christian Engström Vice Chairman, The Swedish Pirate Party.
PADMIN BUCH IPR Innovation & Global Market
What is a trademark? ™.  A trademark is a word, phrase, symbol or design, or a combination thereof, that identifies and distinguishes the source of the.
The Pharmaceutical Composition Methodology described in this presentation has been developed to improve controlled drug delivery through site specific.
Intellectual Property Basics: What Rules Apply to Faculty, Staff, and Student Work Product? Dave Broome Vice Chancellor and General Counsel October 15,
Intellectual Property Choices. Intellectual Property Rights Protection Rights to Choose From Include Protection Rights to Choose From Include Patents.
Nadya Reingand, PhD Yan Hankin, Esq. Washington DC, USA © Copyright. All rights reserved. Intellectual Property and Business Aspects of Digital Holography.
Commercialization Plan Product Development Business model Financial plan BUSINESS PLAN Development strategy Budgets IDEA Invention Preface Fig 1.
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
Intellectual Property as Integral Part of S&T Strategy Dr. Nadya Reingand Patent Hatchery LLC Washington DC, USA © Nadya Reingand.
An Overview of Intellectual Property by John Slaughter September 26, 2009 © John Slaughter All Rights Reserved.
Patent Process and Patent Search 6a Foundations of Technology Standard 3: Students will develop an understanding of the relationships among technologies.
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
iHEA 9th World Congress Sydney, July 8, 2013
Technology Transfer Office
Intellectual Property for Startups
Gestora brasileiro focada exclusivamente na área da saúde.
Median time to internationalisation
Innovative Medicines Initiative:
Croatia, Zagreb, September 4, 2018 Ljiljana Sović Brkičić
What are the types of intellectual property ?
What are the types of intellectual property?
Approach: The Cuban Regulatory Strategy
Presentation transcript:

Protection of Intellectual Property in Canada George Jackowski, Ph.D., KCTJ October 19 th, 2015 Chairman of NAVA Corp.

PROTECTION OF INTELLECTUAL PROPERTY IN CANADA In Canada like Poland, we do not have any homegrown global multinational pharmaceutical companies We have strong homegrown global generic companies →E.g. Apotex – who are more interested in patent litigation and nullifying patents Many Canadian companies are acquired by global multinational pharmaceutical companies (GMNPC) or license out their technologies to GMNPC’s Many GMNPC’s have offices supporting their local sales people, marketing, clinical support, have limited R&D and manufacturing, and tend to significantly utilize FDA approved Contract Manufacturing Organizations (CMO) 2

PROTECTION OF INTELLECTUAL PROPERTY IN CANADA GMNPC’s have worldwide patents with issued Canadian patents protecting the product, indication, distribution and manufacturing Health Canada is very well respected globally and is recognized for its thoroughness & safety of clinical trials, approval process and oversight – hence Canadian approved pharmaceuticals and therapeutics are accepted worldwide 3

PROTECTION OF INTELLECTUAL PROPERTY IN CANADA The drivers for global commercialization of products are: →US patents & US trademarks →US Federal Drug Administration (FDA) approvals Creating a worldwide market for healthcare products and technologies involves filing intellectual property in: USA, Europe, Japan and Canada (local jurisdiction) 4

PROTECTION OF INTELLECTUAL PROPERTY IN CANADA Patent system is expensive, but is excellent for parties (academics and start-ups) with little access to capital who have great ideas Science behind biotech patents today is less about entirely novel breakthroughs (less than 1%) BREAKTHROUGH PRODUCTS and more about the clever combination and extension of existing ideas INNOVATIVE PRODUCTS Protection for 20 years from date of filing 5

PROTECTION OF INTELLECTUAL PROPERTY IN CANADA Our Patent Strategy: 6 US Provisional Patent Filing PCT Filing – European Search Authority US CIP Filing US Patent Issued Patent Prosecution Highway (PPH) – Expedite Review Process European Patent Issued

7 Thank you Dziękuję bardzo